alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › mri

mri

843 studies tagged mri, dated 1983-08-01 to 2026-09-25. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Diagnostic accuracy of remote self-administered digital cognitive assessment by clinical diagnosis and Alzheimer's disease PET imaging biomarkers 2026-09-25
  2. Multi-scale 3D CNN with imbalance-aware training for structural MRI-based six-class Alzheimer disease staging 2026-09-22
  3. T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation 2026-09-21

Studies

843 studies carry this tag.

Date range

1983 to 2026

Top journals

  • Neurology 83
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine 42
  • Brain : a journal of neurology 34
  • NeuroImage 31
  • Alzheimer s & Dementia 30

283 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Diffusion Tensor MRI Structural Connectivity and PET Amyloid Burden in Preclinical Autosomal Dominant Alzheimer Disease: The DIAN Cohort

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Radiology 2021-10-12 Biomarkers

    White matter structural connectivity was lower in autosomal dominant Alzheimer disease mutation carriers compared with noncarriers and correlated with estimated years to symptom onset.

  2. Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-β PET Signal

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Neurology 2021-09-09 Biomarkers

    Forty-one participants (30 male, 11 female) with a mean (SD) age at death of 75.7 (10.6) years were included.

  3. Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET

    ✓ Peer-reviewed alzhub usefulness score 63 out of 100. Neurology 2021-09-09 Biomarkers

    Amyloid accumulation was evaluated in 236 individuals who underwent >1 amyloid PET scan.

  4. Alzheimer's Disease and Frontotemporal Dementia: A Robust Classification Method of EEG Signals and a Comparison of Validation Methods

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Diagnostics (Basel, Switzerland) 2021-08-09 Digital health tools

    Dementia is the clinical syndrome characterized by progressive loss of cognitive and emotional abilities to a degree severe enough to interfere with daily functioning.

  5. Head-to-head comparison of cerebral blood flow single-photon emission computed tomography and 18 F-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Internal medicine journal 2021-08-01 Biomarkers

    Clinicians reported high diagnostic confidence in 83% of 18 F-FDG PET compared to 67% for CBF-SPECT (P = 0.001).

  6. Machine learning for modeling the progression of Alzheimer disease dementia using clinical data: a systematic literature review

    ✓ Peer-reviewed alzhub usefulness score 44 out of 100. JAMIA open 2021-07-01 Digital health tools

    Identifying individuals at risk for progression of AD dementia could potentially help to personalize disease management to plan future care.

  7. GPS driving: a digital biomarker for preclinical Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's research & therapy 2021-06-14 Digital health tools

    The findings suggest that GPS driving may serve as an effective and accurate digital biomarker for identifying preclinical AD among older adults.

  8. Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Molecular neurodegeneration 2021-06-07 Mild cognitive impairment

    Neuropsychiatric symptoms (NPSs) are common in patients with Alzheimer's disease (AD) and are associated with accelerated cognitive impairment and earlier deaths.

  9. Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. NeuroImage. Clinical 2021-06-04 Digital health tools

    This work validates the generalizability of MRI-based classification of Alzheimer's disease (AD) patients and controls (CN) to an external data set and to the task of prediction of conversion to AD in individuals with mild cognitive impairment (MCI).

  10. Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Journal of Alzheimer's disease reports 2021-06-03 Mild cognitive impairment

    This fifteen-year study provides a large database of highly characterized individuals with longitudinal cognitive, imaging and lifestyle data and biofluid collections, to aid in the development of interventions to delay onset, prevent or treat AD.

  11. Cortical Thickness from MRI to Predict Conversion from Mild Cognitive Impairment to Dementia in Parkinson Disease: A Machine Learning-based Model

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Radiology 2021-05-25 Digital health tools

    Cortical thickness from MRI helped predict conversion from mild cognitive impairment to dementia in Parkinson disease at an individual level, with improved performance when integrated with clinical variables. © RSNA, 2021 Online supplemental material is available for this article.

  12. Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. JAMA neurology 2021-05-01 Treatments

    Intensive treatment was associated with a small but statistically significant greater decrease in hippocampal volume compared with standard treatment, consistent with the observation that intensive treatment is associated with greater decreases in total brain volume.

  13. Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel

    ✓ Peer-reviewed alzhub usefulness score 54 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2021-04-15 Mild cognitive impairment

    The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials.

  14. Transfer Learning in Magnetic Resonance Brain Imaging: A Systematic Review

    ✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of imaging 2021-04-01 Digital health tools

    We found 129 articles that applied transfer learning to MR brain imaging tasks.

  15. Clinical Relevance of [18F]Florbetaben and [18F]FDG PET/CT Imaging on the Management of Patients with Dementia

    ✓ Peer-reviewed alzhub usefulness score 44 out of 100. Molecules (Basel, Switzerland) 2021-02-26 Tau biomarkers

    PET of β-Amyloid plaques (Aβ) using [ 18 F ] florbetaben ( [ 18 F ] FBB) and [ 18 F ] fluorodeoxyglucose ( [ 18 F ] FDG) increasingly aid clinicians in early diagnosis of dementia, including Alzheimer's disease (AD), frontotemporal disease, dementia with Lewy bodies, and vascular dementia.

  16. Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. International journal of molecular sciences 2021-02-20 Hippocampus size on brain scans

    Reduced hippocampal volume is a biomarker for neurodegeneration, but atrophy is not an AD-specific measure.

  17. Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration

    ✓ Peer-reviewed alzhub usefulness score 51 out of 100. Alzheimer's research & therapy 2021-02-19 Long-term cohort studies

    Previous research has described distinct subtypes of Alzheimer's disease (AD) based on the differences in regional patterns of brain atrophy on MRI.

  18. Machine Learning Algorithms and Statistical Approaches for Alzheimer's Disease Analysis Based on Resting-State EEG Recordings: A Systematic Review

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. International journal of neural systems 2021-02-16 Digital health tools

    Alzheimer's Disease (AD) is a neurodegenerative disorder and the most common type of dementia with a great prevalence in western countries.

  19. Plasma d-glutamate levels for detecting mild cognitive impairment and Alzheimer's disease: Machine learning approaches

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of psychopharmacology (Oxford, England) 2021-02-15 Digital health tools

    This study aimed to use peripheral plasma d-glutamate levels to differentiate patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) from healthy individuals and to evaluate its prediction ability using machine learning.

  20. Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA neurology 2021-02-01 Biomarkers

    The data set included 18 178 patients, of which 10 991 (60.5%) had MCI and 7187 (39.5%) had dementia (mean [SD] age, 75.8 [6.3] years; 9333 women [51.3%]).

  21. A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Scientific reports 2021-01-29 Digital health tools

    As a result, physicians struggle to interpret these models, and feel it is hard to trust them.

  22. Deep Learning-Based Classification and Voxel-Based Visualization of Frontotemporal Dementia and Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Frontiers in neuroscience 2021-01-21 Long-term cohort studies

    Frontotemporal dementia (FTD) and Alzheimer's disease (AD) have overlapping symptoms, and accurate differential diagnosis is important for targeted intervention and treatment.

  23. A Transfer Learning Approach for Early Diagnosis of Alzheimer's Disease on MRI Images

    ✓ Peer-reviewed alzhub usefulness score 51 out of 100. Neuroscience 2021-01-17 Long-term cohort studies

    Mild cognitive impairment (MCI) detection using magnetic resonance image (MRI), plays a crucial role in the treatment of dementia disease at an early stage.

  24. An MRI-based strategy for differentiation of frontotemporal dementia and Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. Alzheimer's research & therapy 2021-01-12 Long-term cohort studies

    The differential diagnosis of frontotemporal dementia (FTD) and Alzheimer's disease (AD) is difficult due to the overlaps of clinical symptoms.

  25. Modular machine learning for Alzheimer's disease classification from retinal vasculature

    ✓ Peer-reviewed alzhub usefulness score 51 out of 100. Scientific reports 2021-01-08 Digital health tools

    Alzheimer's disease is the leading cause of dementia.

  26. Association of Aβ deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCB-J

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's research & therapy 2021-01-05 Disease mechanisms

    Our findings lend support to a model in which fibrillar Aβ is still accumulating in the early stages of clinical disease but approaching a relative plateau, a point at which Aβ may uncouple from neurodegenerative processes including synaptic loss.

  27. Multi-View Separable Pyramid Network for AD Prediction at MCI Stage by 18F-FDG Brain PET Imaging

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. IEEE transactions on medical imaging 2020-12-29 Long-term cohort studies

    Alzheimer's Disease (AD), one of the main causes of death in elderly people, is characterized by Mild Cognitive Impairment (MCI) at prodromal stage.

  28. Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. JAMA neurology 2020-12-01 Treatments

    Compared with participants who learned that they had a not elevated amyloid result, individuals who learned of an elevated amyloid result were no more likely to experience short-term increases in depression (mean [SD] change in the Geriatric Depression Scale score, 0.02 [1.3] vs 0.04 [1.3]; P = .90), anxiety (mean [SD] change in State-Trait Anxiety Inventory score, -0.02 [3.2] vs -0.15 [3.0]; P = .65), or suicidality (mean [SD] change in the Columbia Suicide Severity Rating Scale score, 0.0 [0.4] vs -0.01 [0.5]; P = .67).

  29. Distinct Brain Functional Impairment Patterns Between Suspected Non-Alzheimer Disease Pathophysiology and Alzheimer's Disease: A Study Combining Static and Dynamic Functional Magnetic Resonance Imaging

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in aging neuroscience 2020-11-23 Tau biomarkers

    It accounts for a quarter of the elderly population and is associated with cognitive decline.

  30. Accelerated MRI-predicted brain ageing and its associations with cardiometabolic and brain disorders

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Scientific reports 2020-11-17 Long-term cohort studies

    Brain structure in later life reflects both influences of intrinsic aging and those of lifestyle, environment and disease.

  31. Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Neurology 2020-11-16 Biomarkers

    These optimized thresholds can help to inform future research and clinical trials targeting early Aβ.

  32. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. The Lancet. Neurology 2020-11-01 Getting a diagnosis

    Various biomarkers are available to support the diagnosis of neurodegenerative diseases in clinical and research settings.

  33. Alzheimer's Disease Detection Through Whole-Brain 3D-CNN MRI

    ✓ Peer-reviewed alzhub usefulness score 51 out of 100. Frontiers in bioengineering and biotechnology 2020-10-30 Digital health tools

    The projected burden of dementia by Alzheimer's disease (AD) represents a looming healthcare crisis as the population of most countries grows older.

  34. EEG microstate complexity for aiding early diagnosis of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 51 out of 100. Scientific reports 2020-10-19 Mild cognitive impairment

    The dynamics of the resting brain exhibit transitions between a small number of discrete networks, each remaining stable for tens to hundreds of milliseconds.

  35. Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Molecular neurodegeneration 2020-09-22 Digital health tools

    Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer's disease (AD) continuum.

  36. Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. International journal of molecular sciences 2020-09-21 Digital health tools

    Easily accessible biomarkers for Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD), and related neurodegenerative disorders are urgently needed in an aging society to assist early-stage diagnoses.

  37. Data-driven discovery of probable Alzheimer's disease and related dementia subphenotypes using electronic health records

    ✓ Peer-reviewed alzhub usefulness score 58 out of 100. Learning health systems 2020-09-10 Digital health tools

    Four subphenotypes were computationally derived that correlated with cardiovascular diseases and mental health illnesses.

  38. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles

    ✓ Peer-reviewed alzhub usefulness score 58 out of 100. Brain : a journal of neurology 2020-09-01 Brain tissue and pathology

    Braak stages of tau neurofibrillary tangle accumulation have been incorporated in the criteria for the neuropathological diagnosis of Alzheimer's disease.

  39. Predicting Alzheimer's disease progression using deep recurrent neural networks

    ✓ Peer-reviewed alzhub usefulness score 65 out of 100. NeuroImage 2020-08-04 Long-term cohort studies

    Early identification of individuals at risk of developing Alzheimer's disease (AD) dementia is important for developing disease-modifying therapies.

  40. Determining Amyloid-β Positivity Using 18F-AZD4694 PET Imaging

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020-07-31 Biomarkers

    We observed good convergence among the 4 Good convergence was obtained among several methods for determining an optimal cutoff for 18 F-AZD4694 PET positivity.

  41. Multitracer model for staging cortical amyloid deposition using PET imaging

    ✓ Peer-reviewed alzhub usefulness score 68 out of 100. Neurology 2020-07-16 Biomarkers

    SUVr abnormality was most frequently observed in cingulate, followed by orbitofrontal, precuneal, and insular cortices and then the associative, temporal, and occipital regions.

  42. 18F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging

    ✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020-07-09 Brain scans and imaging

    In vitro binding assays demonstrated a high binding affinity of 18 F-SMBT-1 to MAO-B (dissociation constant, 3.7 nM).

  43. One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020-07-03 Biomarkers

    Pattern expression strengths predicted amyloid status with a sensitivity of 0.94 and a specificity of 0.83.

  44. Using machine learning to quantify structural MRI neurodegeneration patterns of Alzheimer's disease into dementia score: Independent validation on 8,834 images from ADNI, AIBL, OASIS, and MIRIAD databases

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Human brain mapping 2020-07-02 Digital health tools

    Biomarkers for dementia of Alzheimer's type (DAT) are sought to facilitate accurate prediction of the disease onset, ideally predating the onset of cognitive deterioration.

  45. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA neurology 2020-07-01 Getting a diagnosis

    This study's findings suggest that PET imaging with [18F]flortaucipir could be used to identify the density and distribution of AD-type tau pathology and the presence of high levels of AD neuropathological change, supporting a neuropathological diagnosis of AD.

  46. Cross-sectional and Longitudinal Assessment of Brain Iron Level in Alzheimer Disease Using 3-T MRI

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Radiology 2020-06-30 Brain scans and imaging

    Iron concentration in the deep gray matter and neocortical regions was higher in patients with Alzheimer disease than in healthy control participants.

  47. Sex-driven modifiers of Alzheimer risk: A multimodality brain imaging study

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Neurology 2020-06-24 Genetics

    Groups were comparable on clinical and cognitive measures.

  48. Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Clinical epigenetics 2020-06-15 Mild cognitive impairment

    Our work shows that peripheral differential methylation between age-matched subjects with AD relative to healthy controls will provide opportunities to further investigate and validate differential methylation as a surrogate of disease.

  49. A Machine Learning Approach for the Differential Diagnosis of Alzheimer and Vascular Dementia Fed by MRI Selected Features

    ✓ Peer-reviewed alzhub usefulness score 56 out of 100. Frontiers in neuroinformatics 2020-06-11 Brain scans and imaging

    Among dementia-like diseases, Alzheimer disease (AD) and vascular dementia (VD) are two of the most frequent.

  50. Generalizable, Reproducible, and Neuroscientifically Interpretable Imaging Biomarkers for Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2020-06-09 Digital health tools

    Precision medicine for Alzheimer's disease (AD) necessitates the development of personalized, reproducible, and neuroscientifically interpretable biomarkers, yet despite remarkable advances, few such biomarkers are available.

From across this tag

10 of the 839 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

All topic tags with their study counts